Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

hepatocellular carcinoma

Onco_background

Oncology Today—February 9, 2026

This week's Oncology update , covers regulatory actions, late-stage clinical…

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T

Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…

by Timos Papagatsias

Oncology News

Oncology Video Recap—January 19, 2026

In this week's Oncology update regulatory milestones and late-stage clinical…

ESMO GI 2025_Preview_by_LucidQuest

ESMO GI 2025 Preview: Key Gastrointestinal Oncology Highlights to Watch

ESMO GI 2025 at a glance Get ready for ESMO GI 2025 with LucidQuest’s…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Hematology Today—February 16, 2026
Oncology Video Recap—February 16, 2026
Oncology Today—February 16, 2026
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL

Tags

advanced therapies AI for Science American Stroke Association bioinformatics Biologic therapies Bispecific antibody therapy cancer ckd corporate venture capital drug pricing drug supply chain Elranatamab ESMO 2021 FDA oncology approvals gene editing gene therapy approval Gene therapy innovation Global neuroscience market Helmsley Charitable Trust hematology investment In vivo CRISPR editing Longevity genetics Mass General Brigham nanotechnology NFTs in healthcare non viral vectors Obesity strategy OCEANIC-STROKE Trial oncology trials organizations OpenAI OX40 pathway pharma Pimicotinib Public health market trends Recessive dystrophic epidermolysis bullosa remote patient monitoring Reproductive health therapies Respiratory drug pipeline Sema4 T-cell engagers Tahoe Therapeutics tissue engineering TNFα unconventional trial designs

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Hematology Today—February 16, 2026
Oncology Video Recap—February 16, 2026
Oncology Today—February 16, 2026
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL

TAGS

advanced therapies AI for Science American Stroke Association bioinformatics Biologic therapies Bispecific antibody therapy cancer ckd corporate venture capital drug pricing drug supply chain Elranatamab ESMO 2021 FDA oncology approvals gene editing gene therapy approval Gene therapy innovation Global neuroscience market Helmsley Charitable Trust hematology investment In vivo CRISPR editing Longevity genetics Mass General Brigham nanotechnology NFTs in healthcare non viral vectors Obesity strategy OCEANIC-STROKE Trial oncology trials organizations OpenAI OX40 pathway pharma Pimicotinib Public health market trends Recessive dystrophic epidermolysis bullosa remote patient monitoring Reproductive health therapies Respiratory drug pipeline Sema4 T-cell engagers Tahoe Therapeutics tissue engineering TNFα unconventional trial designs

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy